期刊文献+

Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice 被引量:24

Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice
下载PDF
导出
摘要 Objective: To study the inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice. Methods: Female mice were selected as experimental animals, and breast cancer tumor-bearing mouse models were established and then divided into group A, B, C and D that respectively received saline, recombinant human endostatin, ginsenosides Rg3 and recombinant human endostatin combined with Rg3 intervention; 7 d, 14 d and 21 d after intervention, tumor tissue volume was measured; 21 d after intervention, mice were killed, tumor tissue was collected, and m RNA contents of angiogenesis molecules, invasion molecules, autophagy marker molecules and autophagy signaling pathway molecules were detected. Results: At 7 d, 14 d and 21 d after intervention, tumor tissue volume of group B, C and D was lower than that of group A, and tumor tissue volume of group D was lower than that of group B and C; m RNA contents of VEGFA, VEGFB, VEGFC, MMP2, MMP9, p62, m TOR, PI3 K, Akt, JNK and Beclin-1 in tumor tissue of group B, C and D were significantly lower than those of group A, and LC3-II/LC3-I was significantly higher than that of group A; m RNA contents of VEGFA, VEGFB, VEGFC, MMP2, MMP9, p62, m TOR, PI3 K, Akt, JNK and Beclin-1 in tumor tissue of group D were significantly lower than those of group B and C, and LC3-II/LC3-I was higher than that of group B and C. Conclusions: Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit angiogenesis and cell invasion, and enhance cell autophagy. Objective: To study the inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice. Methods: Female mice were selected as experimental animals, and breast cancer tumor-bearing mouse models were established and then divided into group A, B, C and D that respectively received saline, recombinant human endostatin, ginsenosides Rg3 and recombinant human endostatin combined with Rg3 intervention; 7 d, 14 d and 21 d after intervention, tumor tissue volume was measured; 21 d after intervention, mice were killed, tumor tissue was collected, and mRNA contents of angiogenesis molecules, invasion molecules, autophagy marker molecules and autophagy signaling pathway molecules were detected. Results: At 7 d, 14 d and 21 d after intervention, tumor tissue volume of group B, C and D was lower than that of group A, and tumor tissue volume of group D was lower than that of group B and C; mRNA contents of VEGFA, VEGEB, VEGFC, MMP2, p62, mTOR, PI3K, Akt, JNK and Berlin-1 in tumor tissue of group B, C and D were significantly lower than those of group A. and LC3-IIlLC3-I was significantly higher than that of group A; mRNA contents of VEGFA, VEGFB, VEGFC, MMP2, MMP9, p62, mTOR, PI3K, Akt, JNK and Beclin-1 in tumor tissue of group D were significantly lower than those of group B and C, and LC3-IIIlC3-I was higher than that of group B and C. Conclusions: Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit angiogenesis and cell invasion, and enhance cell autophagy.
出处 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第2期178-181,共4页 亚太热带医药杂志(英文版)
基金 supported by Linyi City Science and Technology Development Plan in 2014(No.201413010)
关键词 Breast cancer RECOMBINANT human ENDOSTATIN GINSENOSIDE RG3 Autophagy Breast cancer Recombinant human endostatin Ginsenoside Rg3 Autophagy
  • 相关文献

参考文献14

  • 1Rigiracciolo DC,Scarpelli A,Lappano R,Pisano A,Santolla MF,De Marco P,et al.Copper activates HIF-1α/GPER/VEGF signalling in cancer cells. Oncotarget . 2015
  • 2Amaral C,Lopes A,Varela CL,da Silva ET,Roleira FM,Correia-daSilva G,et al.Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy:a comparative study with Exemestane. International Journal of Biochemistry Cell Biology The . 2015
  • 3潘晓华,王墨林,崔行.人参皂苷Rg3对乳腺癌细胞增殖的影响及其机制探讨[J].山东医药,2011,51(26):20-22. 被引量:9
  • 4Jianguo Sun,Li Deng,Yuzhong Duan,Fanglin Chen,Xinxin Wang,Dezhi Li,Zhengtang Chen.??Inhibitory effect of endostatin combined with paclitaxel?cisplatin onbreast cancer in xenograft-bearing mice(J)Experimental and Therapeutic Medicine . 2012 (2)
  • 5Jiang WG,Lu XA,Shang BY,et al.Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis. BMC Cancer . 2013
  • 6Li YB,Guo CX,Wang ZC,et al.Radiosensitization of breast cancer cells by TRAIL-endostatin-targeting gene therapy. Neoplasma . 2013
  • 7Xiao-ping Chen,Lin-lin Qian,Hong Jiang.Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY . 2011
  • 8Kim BM,Kim DH,Park JH,et al.Ginsenoside rg3 inhibits constitutive activation of NF-κB signaling in human breast cancer (mda-mb-231)cells:erk and akt as potential upstream targets. J Cancer Prev . 2014
  • 9Kim BM,Kim DH,Park JH,et al.Ginsenoside Rg3 induces apoptosis of human breast cancer (MDA-MB-231)cells. J Cancer Prev . 2013
  • 10Leifler KS,Svensson S,Abrahamsson A,et al.Inflammation induced by mmp-9 enhances tumor regression of experimental breast cancer. J Immunol . 2013

二级参考文献9

  • 1Jia WW, Bu X, Philips D, et al. Rh2, a compound extracted from ginseng, hypersensifizes multidrug-resistant tumor cells to chemotherapy[J]. Can J Physiol Pharmacol, 2004,82(7) :437.
  • 2Nakata H, Kikuehi Y, Tode T, et al. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells[ J]. Jpn J Cancer Res, 1998,89(7) :733-740.
  • 3Dapas B, Farra R, Grassi M, et al. Role of E2F1-Cyclin El-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs[J]. Mol Med, 2009,15(9-10) :297-306.
  • 4Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer: a review [ J ]. Gastric Cancer, 2005,8 (2) :86-94.
  • 5Spruck C, Sun D, Fiegl H, et al. Detection of low molecular weight derivatives of cyelin E1 is a function of cyclin E1 protein levels in breast cancer [ J ]. Cancer Res, 2006,66 ( 14 ) :7355-7360.
  • 6Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy[ J]. Cancer Biol Ther, 2003,2(4 Suppl 1 ) :38-47.
  • 7DonzeUi M, Draetta GF. Regulating mammalian checkpoints through Cde25 inactivation [J]. EMBO Rep, 2003, 4 (7) : 671-677.
  • 8Lehmann GM, MeCabe MJ Jr. Arsenite slows S phase progression via inhibition of CDC25A dual specificity phosphatase gene tran- scription[ J]. Toxieol Sei, 2007,99( 1 ) :70-78.
  • 9Laveeehia A, Di Giovanni C, Novellino E. CDC25A and B dualspecificity phosphatase inhibitors : potential agents for cancer therapy [J]. Curr Med Chem, 2009,16(15) :1831-1849.

共引文献8

同被引文献213

引证文献24

二级引证文献139

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部